Young Shin Song1, Jung Ah Lim1,2, Hoonsung Choi1,3, Jae-Kyung Won4, Jae Hoon Moon1,5, Sun Wook Cho1, Kyu Eun Lee6,7, Young Joo Park1,7, Ka Hee Yi1,8, Do Joon Park1, Jeong-Sun Seo7,9. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 2. Department of Internal Medicine, National Medical Center, Seoul, Korea. 3. Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea. 4. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. 5. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 6. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. 7. Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea. 8. Department of Internal Medicine, Boramae Medical Center, Seoul, Korea. 9. Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes. METHODS: In all, 551 patients with differentiated thyroid cancer (DTC) enrolled in this study. The median follow-up duration was 4.8 years (interquartile range, 3.4-10.6 years). RESULTS: TERT promoter mutations were detected in 25 DTCs (4.5%): 2.8% in neither BRAF-mutated nor RAS-mutated tumors, 4.8% in BRAF-mutated tumors, and 11.3% in RAS-mutated tumors. Moreover, they were frequently observed in American Thyroid Association (ATA) high-risk and TNM stage III/IV groups (9.1% and 12.9%, respectively). The coexistence of BRAF or RAS with TERT promoter mutations increased aggressive clinicopathologic features, recurrence (hazard ratio [HR] for BRAF, 4.64; 95% confidence interval [CI], 1.42-15.18; HR for RAS, 5.36; 95% CI, 1.20-24.02), and mortality (HR for BRAF, 15.13; 95% CI, 1.55-148.23; HR for RAS, 14.75; 95% CI, 1.30-167.00), even after adjustments for the age at diagnosis and sex, although the significance was lost after additional adjustments for pathologic characteristics. Furthermore, TERT promoter mutations significantly increased the risk of both recurrence and mortality in the ATA high-risk (HR for recurrence, 5.79; 95% CI, 2.07-16.18; HR for mortality, 16.16; 95% CI, 2.10-124.15) and TNM stage III/IV groups (HR for recurrence, 3.60; 95% CI, 1.19-10.85; HR for mortality, 9.06; 95% CI, 2.09-39.26). CONCLUSIONS: The coexistence of BRAF or RAS mutations enhanced the prognostic effects of TERT promoter mutations. Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high-risk patients with DTC. Cancer 2016;122:1370-1379.
BACKGROUND: Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes. METHODS: In all, 551 patients with differentiated thyroid cancer (DTC) enrolled in this study. The median follow-up duration was 4.8 years (interquartile range, 3.4-10.6 years). RESULTS:TERT promoter mutations were detected in 25 DTCs (4.5%): 2.8% in neither BRAF-mutated nor RAS-mutated tumors, 4.8% in BRAF-mutated tumors, and 11.3% in RAS-mutated tumors. Moreover, they were frequently observed in American Thyroid Association (ATA) high-risk and TNM stage III/IV groups (9.1% and 12.9%, respectively). The coexistence of BRAF or RAS with TERT promoter mutations increased aggressive clinicopathologic features, recurrence (hazard ratio [HR] for BRAF, 4.64; 95% confidence interval [CI], 1.42-15.18; HR for RAS, 5.36; 95% CI, 1.20-24.02), and mortality (HR for BRAF, 15.13; 95% CI, 1.55-148.23; HR for RAS, 14.75; 95% CI, 1.30-167.00), even after adjustments for the age at diagnosis and sex, although the significance was lost after additional adjustments for pathologic characteristics. Furthermore, TERT promoter mutations significantly increased the risk of both recurrence and mortality in the ATA high-risk (HR for recurrence, 5.79; 95% CI, 2.07-16.18; HR for mortality, 16.16; 95% CI, 2.10-124.15) and TNM stage III/IV groups (HR for recurrence, 3.60; 95% CI, 1.19-10.85; HR for mortality, 9.06; 95% CI, 2.09-39.26). CONCLUSIONS: The coexistence of BRAF or RAS mutations enhanced the prognostic effects of TERT promoter mutations. Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high-risk patients with DTC. Cancer 2016;122:1370-1379.
Authors: Tihana Ibrahimpasic; Bin Xu; Iñigo Landa; Snjezana Dogan; Sumit Middha; Venkatraman Seshan; Shyam Deraje; Diane L Carlson; Jocelyn Migliacci; Jeffrey A Knauf; Brian Untch; Michael F Berger; Luc Morris; R Michael Tuttle; Timothy Chan; James A Fagin; Ronald Ghossein; Ian Ganly Journal: Clin Cancer Res Date: 2017-06-20 Impact factor: 12.531
Authors: Jose R W Martínez; Sergio Vargas-Salas; Soledad Urra Gamboa; Estefanía Muñoz; José Miguel Domínguez; Augusto León; Nicolás Droppelmann; Antonieta Solar; Mark Zafereo; F Christopher Holsinger; Hernán E González Journal: Horm Cancer Date: 2019-03-22 Impact factor: 3.869